AU2020234785A1 - Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents - Google Patents

Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents Download PDF

Info

Publication number
AU2020234785A1
AU2020234785A1 AU2020234785A AU2020234785A AU2020234785A1 AU 2020234785 A1 AU2020234785 A1 AU 2020234785A1 AU 2020234785 A AU2020234785 A AU 2020234785A AU 2020234785 A AU2020234785 A AU 2020234785A AU 2020234785 A1 AU2020234785 A1 AU 2020234785A1
Authority
AU
Australia
Prior art keywords
cancer
amino acid
ctla
domain
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020234785A
Other languages
English (en)
Inventor
Lakshmanan Annamalai
David BAUCHE
Edward Bowman
Alissa Chackerian
Jeffery Grein
Drake Laface
Smita MAUZE
Juha Punnonen
Anandi SAWANT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2020234785A1 publication Critical patent/AU2020234785A1/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Amend patent request/document other than specification (104) Assignors: MERCK SHARP & DOHME CORP.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020234785A 2019-03-13 2020-03-10 Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents Pending AU2020234785A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817749P 2019-03-13 2019-03-13
US62/817,749 2019-03-13
PCT/US2020/021783 WO2020185722A2 (en) 2019-03-13 2020-03-10 Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents

Publications (1)

Publication Number Publication Date
AU2020234785A1 true AU2020234785A1 (en) 2021-08-19

Family

ID=72426465

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020234785A Pending AU2020234785A1 (en) 2019-03-13 2020-03-10 Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents

Country Status (11)

Country Link
US (1) US20220411507A1 (US08124317-20120228-C00009.png)
EP (1) EP3937979A4 (US08124317-20120228-C00009.png)
JP (1) JP2022525071A (US08124317-20120228-C00009.png)
KR (1) KR20210141539A (US08124317-20120228-C00009.png)
CN (1) CN113631189A (US08124317-20120228-C00009.png)
AU (1) AU2020234785A1 (US08124317-20120228-C00009.png)
BR (1) BR112021017892A8 (US08124317-20120228-C00009.png)
CA (1) CA3132198A1 (US08124317-20120228-C00009.png)
MA (1) MA55316A (US08124317-20120228-C00009.png)
MX (1) MX2021010997A (US08124317-20120228-C00009.png)
WO (1) WO2020185722A2 (US08124317-20120228-C00009.png)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7415047B2 (ja) 2020-04-22 2024-01-16 メルク・シャープ・アンド・ドーム・エルエルシー インターロイキン－２受容体βγｃ二量体について偏向され、非ペプチド性水溶性ポリマーにコンジュゲートされたヒトインターロイキン－２コンジュゲート
CN116761889A (zh) * 2021-01-29 2023-09-15 明慧医药（杭州）有限公司 抗原结合蛋白及其用途
AU2022258365A1 (en) * 2021-04-14 2023-11-30 Ad Pharmaceuticals Co., Ltd. Use of antibody in anti-tumor treatment
TW202241512A (zh) * 2021-04-21 2022-11-01 中國商和鉑醫藥（上海）有限責任公司 結合ctla-4的抗體及其用途
KR20230110141A (ko) 2022-01-14 2023-07-21 영남대학교 산학협력단 PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도
WO2023217987A1 (en) * 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
KR20170003692A (ko) * 2014-05-15 2017-01-09 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
EP3600426A4 (en) * 2017-03-31 2021-01-20 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND AN ANTI-CTLA4 ANTIBODY

Also Published As

Publication number Publication date
KR20210141539A (ko) 2021-11-23
EP3937979A4 (en) 2023-03-08
CN113631189A (zh) 2021-11-09
US20220411507A1 (en) 2022-12-29
WO2020185722A3 (en) 2020-11-12
MX2021010997A (es) 2021-10-01
WO2020185722A2 (en) 2020-09-17
EP3937979A2 (en) 2022-01-19
BR112021017892A2 (US08124317-20120228-C00009.png) 2021-12-07
CA3132198A1 (en) 2020-09-17
BR112021017892A8 (pt) 2023-01-31
JP2022525071A (ja) 2022-05-11
MA55316A (fr) 2022-01-19

Similar Documents

Publication Publication Date Title
US20220411507A1 (en) Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents
TWI742423B (zh) 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
TW202202521A (zh) 用於治療癌症之抗ccr8抗體
EP3431102A1 (en) Cell injury inducing therapeutic drug for use in cancer therapy
CN104968364A (zh) 强化免疫调变性Fc融合蛋白的抗癌活性
JP6175590B1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
KR20210153100A (ko) 낮은 pH에서의 결합에 대한 증진된 특이성을 갖는 이필리무맙 변이체
CN114901306A (zh) 用于治疗癌症的疗法
EP2935332B1 (en) Anti-h7cr antibodies
AU2015231180A1 (en) Methods of treating transplant rejection using a domain antibody directed against CD40L
TW201811826A (zh) 抗ｉｃｏｓ抗體
CA3066048A1 (en) Combination therapy
US20200190194A1 (en) Combination therapy
US20240218067A1 (en) Anti-siglec compositions and uses thereof
EP4229094A1 (en) Multispecific binding compounds that bind to pd-l1
WO2023091512A2 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.